site:markets.businessinsider.com

Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million

New Guidance Represents an Increase of $55 Million at the Midpoint from the Prior Range of $350 to $370 MillionStrong U.S. Demand for Amtagvi and ...

19h

Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026

The EADV Congress 2026 will take place September 30 - October 3, 2026 in Vienna, Austria and FCD 2026 will take place on October 8-11, 2026 in Las Vegas, Nevada. Presentation details are below. Title: ...

Niche Releases 2027 School and District Rankings; Introduces New Standalone Rankings and Methodology Updates Across Public and Private Schools

This cycle, Niche split several existing rankings into separate public and private versions, giving families more relevant comparisons within each school type: Best Schools for the Arts, Most Diverse ...

Business Insider

Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million

Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026

Niche Releases 2027 School and District Rankings; Introduces New Standalone Rankings and Methodology Updates Across Public and Private Schools

iShares Core U.S. Aggregate Bond ETF

State Street® Technology Select Sector SPDR® ETF

Roundhill Magnificent Seven ETF

Vanguard Information Technology Index Fund ETF Shares

iShares MSCI Emerging Markets ETF

Vanguard S&P 500 Growth Index Fund ETF Shares

State Street® Industrial Select Sector SPDR® ETF

iShares MSCI Emerging Markets Asia ETF

State Street® Health Care Select Sector SPDR® ETF